News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
ImaRx Therapeutics Acquires Abbokinase
May 8, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
TUCSON, Ariz.--(BUSINESS WIRE)--May 8, 2006--ImaRx Therapeutics, Inc., a biopharmaceutical company developing innovative therapies for vascular diseases including stroke, today announced the Company has acquired the thrombolytic drug Abbokinase®.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
Arizona
MORE ON THIS TOPIC
Deals
Travere beefs up rare kidney disease portfolio with up to $1.1B China deal
June 3, 2026
·
2 min read
·
Tristan Manalac
RNA editing
Lilly targets kidney disease with Ascidian’s RNA exon editors for up to $1.9B
June 3, 2026
·
2 min read
·
Tristan Manalac
Podcast
ASCO wins from RevMed, Akeso/Summit, more; plus more Lilly and more China; ADA on deck
June 3, 2026
·
2 min read
·
Jef Akst
China
Lilly bets $3B+ to add China’s Haisco to growing list of partners in five-program pact
June 2, 2026
·
1 min read
·
Tristan Manalac
